Tesla said shareholders voted in favor of CEO Elon Musk's almost $1 trillion pay plan, with 75% support. Board members recommended shareholders approve the pay plan, which they introduced in September. Top proxy advisors Glass Lewis and ISS recommended voting against it.Results of the vote were announced on Thursday at the company's annual shareholders meeting in Austin, Texas. The package for Musk, already the world's richest person, consists of 12 tranches of shares to be granted if Tesla hits certain mil ...

Peloton on Thursday posted its second profitable quarter in a row as it released strong guidance for the crucial holiday shopping season, banking on its relaunched product assortment to drive growth. The connected fitness company posted a surprise net income of $13.9 million in the three months ended Sept. 30, compared with a loss of $900,000 a year earlier. For the current quarter, Peloton's strongest for hardware sales, the company is expecting revenue to be between $665 million and $685 million, a slight ...

Shares of Airbnb rose as much as 5% in extended trading on Thursday after the company reported third-quarter results that beat analysts' estimates for revenue and offered rosy guidance.Here's how the company did based on average analysts' estimates compiled by LSEG:Earnings per share: $2.21 vs. $2.34 cents expectedRevenue: $4.10 billion vs. $4.08 billion expectedRevenue increased 10% from $3.73 billion during the same period last year. The company reported net income of $1.374 billion, or $2.21 per share, u ...

Core Viewpoint - Take-Two Interactive Software's shares dropped 10% in after-hours trading following the announcement of a delay in the release of Grand Theft Auto VI to November 2026, which was initially scheduled for fall 2025 [1][2]. Group 1: Company Announcement - Rockstar Games stated that the additional time is necessary to ensure the game meets the expected level of polish [1]. - The new launch date for Grand Theft Auto VI is set for November 19, 2026 [2]. Group 2: Market Reaction - The announcement of the delay led to a significant decline in Take-Two Interactive's stock price, reflecting investor disappointment [1].

Virtual care company Omada Health on Thursday said it will start prescribing GLP-1s and other obesity drugs and helping patients manage those medications.Omada plans to expand the offerings under its weight management program as its membership grows to more than 100,000. The announcement comes as digital health companies increase their presence in the blockbuster market for GLP-1s to treat obesity, diabetes and other chronic conditions – a space that could be worth roughly $100 billion by the end of the dec ...

McDonald's leadership is urging operators to stay the course on value offerings as the competition for consumers plays out across the restaurant space. In a memo to U.S. operators following the company's third-quarter earnings, McDonald's U.S. President Joe Erlinger said the brand was "moving in the right direction" as it continues a more-than-yearlong push on value."Amid industry pressures, dynamic change, and aggressive competition, winning the fight for contracting traffic means staying customer-obsessed ...

Core Viewpoint - Ford Motor is considering ending production of its all-electric F-150 Lightning pickup truck due to increasing losses and challenging market conditions for electric vehicles (EVs) [1][2]. Group 1: Production and Sales - The F-150 Lightning is currently the best-selling electric pickup truck in the U.S., achieving record sales in Q3 despite competition from models like CyberTruck and Rivian [3]. - Ford has paused production of the Lightning due to supply chain disruptions caused by a fire at Novelis, a key supplier [4]. - Sales of the F-150 Lightning this year through October are approximately 24,577 units, remaining level compared to the previous year, with total sales since its launch in 2022 being less than 100,000 units [5]. Group 2: Financial Performance - Ford's EV operations, including the Lightning, have incurred billions of dollars in losses annually in recent years [6]. - The U.S. EV market is facing significant regulatory changes, including the elimination of consumer credits of up to $7,500 for EV purchases, which may impact sales [6]. Group 3: Industry Context - The discussions regarding the F-150 Lightning's future come after Stellantis decided to halt plans for an all-electric Ram 1500 pickup and General Motors scaled back its electric truck plans [7].

Core Insights - Retailers are expected to hire between 265,000 and 365,000 seasonal workers this year, marking the lowest number in at least 15 years [1][2] - This hiring expectation reflects a softening labor market, with a significant drop from last year's 442,000 seasonal hires [2] - Companies are managing higher costs from tariffs and have limited spending, which may have led to early hiring for sales events in October [2] Employment Trends - Layoff announcements surged to 153,074 in October, a 183% increase from September and a 175% rise from the same month last year, the highest for any October since 2003 [4] - 2025 is projected to be the worst year for announced layoffs since 2009 [4] - Conversely, ADP reported a net job growth of 42,000 in October, reversing two months of losses in the private sector [4] Economic Context - The ongoing government shutdown has resulted in fewer government reports on economic data, leading companies and economists to rely on private data sources [3]

Core Insights - The Trump administration has reached agreements with Eli Lilly and Novo Nordisk to significantly reduce the prices of their weight loss drugs, making them more accessible to patients [1][4]. Pricing Structure - Monthly out-of-pocket costs for the weight loss injections and upcoming pills will range from $50 to $350, depending on dosage and insurance coverage [2]. - Current GLP-1 drugs, such as Zepbound and Wegovy, have list prices exceeding $1,000 per month, limiting patient access [3]. Medicare Coverage - Starting mid-2026, Medicare will cover GLP-1 drugs for obesity for the first time, potentially increasing access for seniors [5]. - Certain Medicare patients will pay a copay of $50 per month for approved uses of GLP-1 drugs, including obesity treatment [5]. Eligibility Criteria - Eligibility for GLP-1 drugs under Medicare is limited to three cohorts: individuals with a BMI greater than 27, those with obesity and specific health conditions, and patients with severe obesity (BMI greater than 35) [9]. Direct-to-Consumer Pricing - The TrumpRx platform will offer GLP-1s at lower prices, starting at $350 per month and expected to drop to $250 within two years [7]. - Eli Lilly plans to reduce prices on its direct-to-consumer platform, LillyDirect, with Zepbound available for $299 per month at the lowest dose [11]. Medicaid Coverage - Novo Nordisk and Eli Lilly will extend lower government pricing of $245 per month for GLP-1 drugs to all 50 Medicaid programs, although states must opt into these prices [12].

Core Insights - Meta Platforms Inc. projected that approximately 10% of its overall sales in 2024, equating to about $16 billion, will come from online ads related to scams and banned goods [1][2][6] - The company reported total sales exceeding $164.5 billion for 2024, with a 26% year-over-year increase in third-quarter sales to $51.24 billion [3] - Internal documents revealed that Meta generates around $7 billion annually from "higher risk" scam ads, with an estimated 15 billion of these ads shown daily [4] Advertising Practices - The types of ads contributing to the projected sales include promotions for fraudulent e-commerce, illegal online casinos, and banned medical products [2] - Despite efforts to reduce fraudulent ads, there are concerns within the company that removing these ads abruptly could negatively impact business projections [5] Company Response - A Meta spokesperson stated that the estimate of 10% of ad sales from fraudulent ads was a rough approximation and that many of these ads were not in violation of policies [6] - The spokesperson emphasized that the leaked documents provide a selective view of the company's efforts to combat fraud, focusing on the assessment of the issue rather than the comprehensive actions taken [7]